Ginsenoside Suppresses Triple-Negative Breast Cancer Growth and Synergizes With Programmed Cell Death Protein 1 (PD-1) Immunotherapy Through Gut Microbiota and Metabolic Regulation - PubMed
4 hours ago
- #Triple-negative breast cancer
- #Gut microbiota
- #Ginsenoside Rg3
- Ginsenoside Rg3 suppresses triple-negative breast cancer (TNBC) growth and enhances PD-1 immunotherapy efficacy.
- TNBC lacks estrogen receptor, progesterone receptor, and HER2, making treatment challenging.
- PD-1/PD-L1 immunotherapy shows promise for TNBC, but no specific medicines exist yet.
- Gut microbiota and metabolites play a crucial role in modulating TNBC treatment outcomes.
- Rg3 reshapes the tumor microenvironment by promoting M1 macrophage polarization and increasing CD8+ and memory T cells.
- Combination therapy of Rg3 and PD-1 mAb enhances tumor suppression, apoptosis, and immune response.
- Gut microbiota composition and specific metabolites (e.g., Bacteroides vulgatus and sulforaphane-cysteine) influence treatment success.
- Traditional Chinese Medicine (TCM) is gaining attention in cancer therapy, with Rg3 as a potential candidate.